c2.WP TRANSLATION INHIBITORS IN CHRONICALLY ACTIVATED PDGFRA CELLS c2.REACTOME INTRA GOLGI AND RETROGRADE GOLGI TO ER TRAFFIC c2.KEGG GLIOMA c2.REACTOME REGULATION OF CDH11 MRNA TRANSLATION BY MICRORNAS c2.WP HIF1A AND PPARG REGULATION OF GLYCOLYSIS c2.KYNG RESPONSE TO H2O2 c2.NIKOLSKY BREAST CANCER 10Q22 AMPLICON c2.REACTOME CLATHRIN MEDIATED ENDOCYTOSIS c2.KIM LIVER CANCER POOR SURVIVAL UP	and epithelioid t	t Gliomas	lioneuronal tumoi	
C2.RIM LIVER CANCER POOR SURVIAL UP C2.PID NEPHRIN NEPH1 PATHWAY C2.NABA MATRISOME HIGHLY METASTATIC BREAST CANCER TUMOR CELL DERIVED C2.PID AVB3 INTEGRIN PATHWAY C2.REACTOME REGULATION OF PYRUVATE METABOLISM C2.BIOCARTA ERK PATHWAY C2.BIOCARTA PLC PATHWAY C2.BIOCARTA PLC PATHWAY C2.REACTOME APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B C2.REACTOME APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B C2.REACTOME APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B C2.REACTOME NOT SURVEY OF COLOR C2.REACTOME NOT SURVEY OF COLOR C2.REACTOME NOT SURVEY OF COLOR C2.SESTO RESPONSE TO UV C1 C2.PID LYMPH ANGIOGENESIS PATHWAY C2.CHENG RESPONSE TO NICKEL ACETATE C2.REACTOME MASTL FACILITATES MITOTIC PROGRESSION C2.REACTOME SIRVALING SIRVALING PROGRESSION C2.REACTOME SIRVALING SIRVALING PATHWAY C2.KEGG MEDICUS VARIANT AMPLIFIED EGFR TO PLCG CAMK SIGNALING PATHWAY C2.HAHTOLA MYCOSIS FUNGOIDES SKIN DN				
c2.KEGG MEDICUS PATHOGEN ESCHERICHIA TIR TO TLR2 4 MAPK SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE ACH CHRN RAS ERK SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE ACH CHRN RAS ERK SIGNALING PATHWAY c2.REACTOME SIGNALING BY FGFR2 c2.WENDT COHESIN TARGETS UP c2.REACTOME DISASSEMBLY OF THE DESTRUCTION COMPLEX AND RECRUITMENT OF AXIN TO THE MEMBRANE c2.DASU IL6 SIGNALING DN c2.CHESLER BRAIN QTL TRANS c2.WP SEROTONIN RECEPTOR 467 AND NR3C SIGNALING C2.WP PERTURBATIONS TO HOSTCELL AUTOPHAGY INDUCED BY SARSCOV2 PROTEINS c2.PID INSULIN PATHWAY c2.PID INSULIN PATHWAY c2.PID INSULIN PATHWAY c2.RHODES CANCER META SIGNATURE c2.DE YY1 TARGETS DN c2.KEGG MEDICUS REFERENCE IGG FCGR RAC SIGNALING PATHWAYS c2.REACTOME SUMO IS PROTEOLYTICALLY PROCESSED				
C2.REACTOME SIGNALING BY BRAF AND RAF1 FUSIONS C2.BIOCARTA LONGEVITY PATHWAY C2.REACTOME NEGATIVE REGULATION OF FGFR1 SIGNALING C2.REACTOME MRNA SPLICING MINOR PATHWAY C2.KEGG MEDICUS REFERENCE AGE RAGE SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE AGE RAGE SIGNALING PATHWAY C2.REACTOME SENESCENCE ASSOCIATED SECRETORY PHENOTYPE SASP C2.REACTOME ONCOGENE INDUCED SENESCENCE C2.REACTOME ONCOGENIC MAPK SIGNALING C2.REACTOME ONCOGENIC MAPK SIGNALING C2.REACTOME ONCOGENIC MAPK SIGNALING C2.REACTOME P75NTR SIGNALS VIA NF KB C2.REACTOME P75NTR SIGNALS VIA NF KB C2.REACTOME CASPASE MEDIATED CLEAVAGE OF CYTOSKELETAL PROTEINS C2.REACTOME TGF BETA RECEPTOR SIGNALING IN EMT EPITHELIAL TO MESENCHYMAL TRANSITION C2.KEGG MEDICUS REFERENCE ACTIVATION OF PRC2.2 BY UBIQUITINATION OF H2AK119 IN GERMLINE GENES C2.REACTOME TGF BETA RECEPTOR SIGNALING IN EMT EPITHELIAL TO MESENCHYMAL TRANSITION C2.MYLLYKANGAS AMPLIFICATION HOT SPOT 5 C2.REACTOME REGULATION OF TP53 EXPRESSION AND DEGRADATION C2.MYLLYKANGAS AMPLIFICATION HOT SPOT 5 C2.REACTOME REGULATION OF TP53 EXPRESSION AND DEGRADATION				
c2.MA RAT AGING DN c2.SCHLOSSER SERUM RESPONSE DN c2.KARLSON TGF81 TARGETS UP c2.SA TRKA RECEPTOR c2.REACTOME TCR SIGNALING c2.SCHAEFFER PROSTATE DEVELOPMENT AND CANCER BOX1 UP c2.IIZUKA LIVER CANCER PROGRESSION G2 G3 DN c2.HENDRICKS SMARCA4 TARGETS UP c2.REACTOME HOM INFECTION c2.KEGG MEDICUS PATHOGEN SHIGELLA OSPF TO TLR2 4 MAPK SIGNALING PATHWAY c2.ABBUD LIF SIGNALING 2 UP c2.REACTOME INFECTIOUS DISEASE c2.AMIT EGF RESPONSE 20 MCF10A c2.BIOCARTA HER2 PATHWAY c2.REACTOME INTERLEUKIN 35 SIGNALLING c2.WP IL11 SIGNALING c2.DIAZ CHRONIC MYELOGENOUS LEUKEMIA UP c2.BIOCARTA PRC2 PATHWAY c2.DIAZ CHRONIC MYELOGENOUS LEUKEMIA UP c2.BIOCARTA PRC2 PATHWAY				
c2.REACTOME P75NTR RECRUITS SIGNALLING COMPLEXES c2.REACTOME P75NTR RECRUITS SIGNALLING COMPLEXES c2.REACTOME SIGNALING BY EGFR c2.RICKMAN TUMOR DIFFERENTIATED MODERATELY VS POORLY DN c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO VGCC CA2 APOPTOTIC PATHWAY NO1004 c2.WP TROP2 REGULATORY SIGNALING c2.SCHAEFFER PROSTATE DEVELOPMENT 6HR DN c2.FAELT B CLL WITH VH REARRANGEMENTS DN c2.REACTOME DISINHIBITION OF SNARE FORMATION c2.BIOCARTA PLCE PATHWAY c2.LANDIS ERBB2 BREAST TUMORS 65 UP c2.REACTOME POSITIVE EPIGENETIC REGULATION OF RRNA EXPRESSION c2.KEGG MEDICUS REFERENCE ASSEMBLY AND TRAFFICKING OF TELOMERASE c2.MUELLER COMMON TARGETS OF AML FUSIONS UP c2.REACTOME REGULATION OF GLYCOLYSIS BY FRUCTOSE 2 6 BISPHOSPHATE METABOLISM c2.CHIBA RESPONSE TO TSA				
c2.REACTOME SIGNALING BY NOTCH1 HD DOMAIN MUTANTS IN CANCER c2.REACTOME TICAM1 TRAF6 DEPENDENT INDUCTION OF TAK1 COMPLEX c2.OZANNE AP1 TARGETS UP c2.OZANNE AP1 TARGETS UP c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS CYAN UP c2.MARTIN INTERACT WITH HDAC c2.MARTIN INTERACT WITH HDAC c2.HAHTOLA MYCOSIS FUNGOIDES SKIN UP c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 13 c2.REACTOME RHOF GTPASE CYCLE c2.APPIERTO RESPONSE TO FENRETINIDE DN c2.ONGUSAHA BRCA1 TARGETS UP c2.STARK HYPPOCAMPUS 22Q11 DELETION UP c2.HAHTOLA MYCOSIS FUNGOIDES CD4 DN c2.WP MIRNA TARGETS IN ECM AND MEMBRANE RECEPTORS c2.APPIERTO RESPONSE TO FENRETINIDE UP c2.REACTOME METABOLISM OF NITRIC OXIDE NOS3 ACTIVATION AND REGULATION c2.BYSTROEM CORRELATED WITH IL5 DN c2.SCHAEFFER SOX9 TARGETS IN PROSTATE DEVELOPMENT DN c2.SCHAEFFER SOX9 TARGETS IN PROSTATE DEVELOPMENT DN C2.SCHAEFFER SOX9 TARGETS IN PROSTATE DEVELOPMENT DN SEDIM				
c2.SCHLOSSER MYC TARGETS REPRESSED BY SERUM c2.KOINUMA COLON CANCER MSI DN c2.PID ALK1 PATHWAY c2.PARK HSC MARKERS c2.KEGG RENAL CELL CARCINOMA c2.JIANG MELANOMA TRM9 CD8 c2.PID IFNG PATHWAY c2.REACTOME MATERNAL TO ZYGOTIC TRANSITION MZT c2.BIOCARTA TGFB PATHWAY c2.PID GMCSF PATHWAY c2.PID GMCSF PATHWAY c2.PID GMCSF PATHWAY c2.REACTOME DETOXIFICATION OF REACTIVE OXYGEN SPECIES c2.IRITANI MAD1 TARGETS DN c2.WP NONALCOHOLIC FATTY LIVER DISEASE c2.KEGG MEDICUS ENV FACTOR NNK NNN TO RAS ERK SIGNALING PATHWAY c2.REACTOME HDL ASSEMBLY c2.BIOCARTA GHELIN PATHWAY c2.BIOCARTA GHELIN PATHWAY c2.BIOCARTA GHELIN PATHWAY				
c2.REACTOME NEGATIVE REGULATION OF MAPK PATHWAY c2.REACTOME ACTIVATED NTRK2 SIGNALS THROUGH FRS2 AND FRS3 c2.REACTOME BETA CATENIN INDEPENDENT WNT SIGNALING c2.REACTOME RECEPTOR MEDIATED MITOPHAGY c2.ID PS1 PATHWAY c2.WP ARACHIDONATE EPOXYGENASE EPOXIDE HYDROLASE c2.REACTOME REGULATION OF ENDOGENOUS RETROELEMENTS BY THE HUMAN SILENCING HUB HUSH COMPLEX c2.REACTOME SIGNALING BY LTK c2.WU HBX TARGETS 1 DN c2.WP IL7 SIGNALING c2.REACTOME ESTABLISHMENT OF SISTER CHROMATID COHESION c2.REACTOME SIGNALING BY THE B CELL RECEPTOR BCR c2.SIMBULAN UV RESPONSE IMMORTALIZED DN c2.REACTOME SIGNALING BY NTRK2 TRKB c2.WP RIOK1 AND RIOK2 IN EGFR AND PI3KMEDIATED TUMORIGENESIS c2.KEGG MEDICUS REFERENCE FLT3LG FLT3 RAS PI3K SIGNALING PATHWAY c2.ROZANOV MMP14 TARGETS SUBSET				
C2. PID ER NONGENOMIC PATHWAY C2. GRATIAS RETINOBLASTOMA 16Q24 c2. KEGG MEDICUS REFERENCE TRAPPI RAB1 SIGNALING PATHWAY C2. REACTOME RHOV GTPASE CYCLE C2. BIOCARTA AKT PATHWAY C3. BIOCARTA PATP PATHWAY C3. BIOCARTA PATP PATHWAY C4. BLACK ALZHEIMERS DISEASE DN C5. WP LEPTIN SIGNALING C5. REACTOME C TYPE LECTIN RECEPTORS CLRS C5. REACTOME ATTENUATION PHASE C5. KEGG MEDICUS REFERENCE CD80 CD86 CTLA4 PP2A SIGNALING PATHWAY C5. SAKAI TUMOR INFILTRATING MONOCYTES DN C5. REACTOME NEF MEDIATES DOWN MODULATION OF CELL SURFACE RECEPTORS BY RECRUITING THEM TO CLATHRIN ADAPTERS C5. WP EFFERS MEDIATES TRANSPORT C5. REACTOME ABC FAMILY PROTEINS MEDIATED TRANSPORT C6. BIOCARTA DREAM PATHWAY C6. SHARLINGER B CLL WITH 17P13 DELETION C6. REACTOME ABC FAMILY PROTEINS MEDIATED TRANSPORT C6. BIOCARTA DREAM PATHWAY C6. SHARLINGER B CLL WITH 17P13 DELETION C6. REACTOME ABC FAMILY PROTEINS MEDIATED TRANSPORT C6. BIOCARTA ABC FAMILY PROTEINS MEDIATED TRANSPORT C6. BIOCARTA ABC FAMILY PROTEINS MEDIATED TRANSPORT C7. BIOCARTA ABC FAMILY PATH				
c2.KEGG MEDICUS REFERENCE CA2 CAM CN SIGNALING PATHWAY c2.KEGG NEUROTROPHIN SIGNALING PATHWAY c2.KEGG NEUROTROPHIN SIGNALING PATHWAY c2.REACTOME DEFECTIVE INTRINSIC PATHWAY FOR APOPTOSIS c2.DORSAM HOXA9 TARGETS DN c2.REACTOME ASSEMBLY OF THE HIV VIRION c2.REACTOME ASSEMBLY OF THE HIV VIRION c2.REACTOME ACTIVATION OF RAS IN B CELLS c2.REACTOME HSF1 ACTIVATION c2.REACTOME HSF1 ACTIVATION c2.WP LINOLEIC ACID METABOLISM AFFECTED BY SARSCOV2 c2.REACTOME SIGNALING BY CSF3 G CSF c2.SPIRA SMOKERS LUNG CANCER UP c2.BIOCARTA UCALPAIN PATHWAY c2.MARTORIATI MDM4 TARGETS FETAL LIVER DN c2.WP VEGFAVEGFR2 SIGNALING C2.SUNG METASTASIS STROMA UP c2.REACTOME UB SPECIFIC PROCESSING PROTEASES c2.BLALOCK ALZHEIMERS DISEASE INCIPIENT DN c2.REACTOME UB SPECIFIC PROCESSING PROTEASES c2.BLALOCK ALZHEIMERS DISEASE INCIPIENT DN c2.RAMPON ENRICHED LEARNING ENVIRONMENT EARLY DN				
c2.KEGG MEDICUS VARIANT BCR ABL FUSION KINASE TO PI3K SIGNALING PATHWAY c2.REACTOME PROCESSING AND ACTIVATION OF SUMO c2.REACTOME MET PROMOTES CELL MOTILITY C2.WP PI3KAKTMTOR SIGNALING AND THERAPEUTIC OPPORTUNITIES IN PROSTATE CANCER c2.REACTOME PROCESSING OF INTRONLESS PRE MRNAS c2.REACTOME THE ROLE OF NEF IN HIV 1 REPLICATION AND DISEASE PATHOGENESIS c2.KEGG MEDICUS REFERENCE BETA OXIDATION c2.KEGG MEDICUS REFERENCE BETA OXIDATION c2.LOPEZ MBD TARGETS IMPRINTED AND X LINKED c2.WP CANONICAL AND NONCANONICAL TGFB SIGNALING c2.REACTOME INTERLEUKIN 27 SIGNALING c2.REACTOME INTERLEUKIN 27 SIGNALING c2.WP PROLACTIN SIGNALING c2.WP PROLACTIN SIGNALING c2.WP PROLACTIN SIGNALING c2.WP G13 SIGNALING c2.WP G13 SIGNALING c2.BIOCARTA PAR1 PATHWAY c2.REACTOME HUR ELAVL1 BINDS AND STABILIZES MRNA c2.PID S1P S1P1 PATHWAY c2.FAELT B CLL WITH VH REARRANGEMENTS UP				
c2.HOLLEMAN DAUNORUBICIN B ALL UP c2.MILI PSEUDOPODIA HAPTOTAXIS UP c2.WP CORI CYCLE c2.BIOCARTA HDAC PATHWAY c2.WP GASTRIN SIGNALING c2.WP GASTRIN SIGNALING c2.BIOCARTA RNA PATHWAY c2.WP ANGIOTENSIN II RECEPTOR TYPE 1 PATHWAY c2.REACTOME LDL CLEARANCE c2.MCBRYAN PUBERTAL TGFB1 TARGETS UP c2.MUNSHI MULTIPLE MYELOMA UP c2.SCIBIT TGFB1 TARGETS UP c2.DORN ADENOVIRUS INFECTION 12HR DN c2.DORN ADENOVIRUS INFECTION 12HR DN c2.SCIBETTA KDM5B TARGETS UP c2.BIOCARTA FMLP PATHWAY c2.REACTOME STAT3 NUCLEAR EVENTS DOWNSTREAM OF ALK SIGNALING c2.WP PRION DISEASE PATHWAY c2.REACTOME PTK6 REGULATES PROTEINS INVOLVED IN RNA PROCESSING				
c2.REACTOME SIGNALING BY FGFR1 c2.REACTOME NTRK2 ACTIVATES RAC1 c2.MILI PSEUDOPODIA CHEMOTAXIS DN c2.WP ANGIOGENESIS c2.PID P38 MK2 PATHWAY c2.LUI THYROID CANCER CLUSTER 4 c2.REACTOME RUNX3 REGULATES P14 ARF c2.REACTOME RUNX3 REGULATES P14 ARF c2.REACTOME EARLY SARS COV 2 INFECTION EVENTS c2.GHO ATF5 TARGETS DN c2.DAVICIONI PAX FOXO1 SIGNATURE IN ARMS DN c2.BERNJENO TRANSFORMED BY RHOA DN c2.REACTOME TRANSCRIPTIONAL REGULATION BY VENTX c2.REACTOME NRIF SIGNALS CELL DEATH FROM THE NUCLEUS c2.DONN ADENOVIRUS INFECTION 32HR DN c2.REACTOME NRIF SIGNALS CELL DEATH FROM THE NUCLEUS c2.DORN ADENOVIRUS INFECTION 32HR DN c2.REACTOME DN ADENOVIRUS INFECTION 32HR DN c2.REACTOME DN ADENOVIRUS INFECTION 32HR DN c2.REACTOME TRANSCRIPTION AND ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1 c2.WP CAMKK2 PATHWAY c2.LIU NASOPHARYNGEAL CARCINOMA c2.REACTOME CTLL4 INHIBITORY SIGNALING				
c2.PETRETTO LEFT VENTRICLE MASS QTL CIS DN c2.UNTERMAN PROGRESSIVE VS STABLE IPF B CELL DN c2.MINGUEZ LIVER CANCER VASCULAR INVASION UP c2.MIP EBOLA VIRUS INFECTION IN HOST c2.BIOCARTA TERT PATHWAY c2.BIOCARTA TERT PATHWAY c2.REACTOME CARGO CONCENTRATION IN THE ER c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SNCA TO VGCC CA2 APOPTOTIC PATHWAY c2.KEGG VALINE LEUCINE AND ISOLEUCINE BIOSYNTHESIS c2.REACTOME PKMTS METHYLATE HISTONE LYSINES c2.BIOCARTA TERC PATHWAY c2.WP HISTONE MODIFICATIONS c2.FEALT B CLL WITH VH3 21 DN c2.BIOCARTA VIP PATHWAY c2.KREPPEL CD99 TARGETS DN c2.REACTOME CATION COUPLED CHLORIDE COTRANSPORTERS				
c2.BASSO B LYMPHOCYTE NETWORK c2.WP EFFECTS OF MFN2 MUTATION c2.TOOKER GEMCITABINE RESISTANCE DN c2.BURTON ADIPOGENESIS 7 c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED KRAS NRAS TO PI3K SIGNALING PATHWAY c2.DITTMER PTHLH TARGETS DN c2.BIOCARTA AKAPCENTROSOME PATHWAY c2.BIOCARTA AKAPCENTROSOME PATHWAY c2.BIOCARTA RARRX PATHWAY c2.BIOCARTA RARRX PATHWAY c2.HOLLEMAN DAUNORUBICIN B ALL DN c2.REACTOME MET ACTIVATES RAS SIGNALING c2.GUENTHER GROWTH SPHERICAL VS ADHERENT DN c2.DORN ADENOVIRUS INFECTION 48HR DN c2.WP 4HYDROXYTAMOXIFEN DEXAMETHASONE AND RETINIOIC ACIDS REGULATION OF P27 EXPRESSION c2.REACTOME SEMAPHORIN INTERACTIONS c2.CALORA GREGULATED BY MYC DN c2.FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR DN c3.FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR DN c4.FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR DN c4.FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR DN c4.FLECHNER BIOPSY KIDNEY TRANSPLA				
C2. RAGHAVACHARI PLATELET SPECIFIC GENES C2. SCHAEFFER PROSTATE DEVELOPMENT AND CANCER BOX4 UP C2. WP OSTEOPONTIN SIGNALING C2. REACTOME OXIDATIVE STRESS INDUCED SENESCENCE C2. KEGG LONG TERM POTENTIATION C2. KEGG CHRONIC MYELOID LEUKEMIA C2. JIANG TIP30 TARGETS DN C2. KEGG CHRONIC MYELOID LEUKEMIA C2. JIANG TIP30 TARGETS DN C2. KEGG MEDICUS REFERENCE ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS II MOLECULES C2. WP METABOLIC PATHWAYS OF FIBROBLASTS C2. PIONTEK PKD1 TARGETS DN C2. PROVENZANI METASTASIS DN C2. PROVENZANI METASTASIS DN C2. PROVENZANI METASTASIS DN C2. PROVENZANI METASTASIS DN C3. PRUIECKNER TARGETS D. PMIRI ETZAS DN				
c2.BRUECKNER TARGETS OF MIRLETTAS DN c2.CAFFAREL RESPONSE TO THC 24HR 3 DN c2.BIOCARTA BCR PATHWAY c2.LU AGING BRAIN DN c2.FERRANDO T ALL WITH MILL ENION UP c2.REACTOME TRANSCRIPTIONAL REGULATION BY RUNX2 c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 7 c2.LEE AGING MUSCLE UP c2.REACTOME ASSOCIATION OF TRIC CCT WITH TARGET PROTEINS DURING BIOSYNTHESIS c2.YASON RESPONSE TO GONADOTROPHINS UP c2.REACTOME MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES c2.REACTOME TRANSLATION OF SARS COV 2 STRUCTURAL PROTEINS c2.REACTOME PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA c2.LANG MYB FAMILY TARGETS c2.REACTOME PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA c2.LANG MYB FAMILY TARGETS c2.REACTOME PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA c2.LANG MYB FAMILY TARGETS c2.WHITFIELD CELL CYCLE M G1 c2.ENK UV RESPONSE KERATINOCYTE DN c2.REACTOME LOSS OF FUNCTION OF SMADS 3 IN CANCER				
C2.REACTOME LOSS OF FUNCTION OF SMAD2 3 IN CANCER C2.REACTOME EGR2 AND SOX10 MEDIATED INITIATION OF SCHWANN CELL MYELINATION C2.WP MELANOMA C2.UNTERMAN IPF VS CTRL NK CELL DN C2.KYNG RESPONSE TO H202 VIA ERCC6 C2.PLASARI TGFB1 TARGETS 1HR DN C2.WP MIRNA REGULATION OF PROSTATE CANCER SIGNALING C2.SASSON RESPONSE TO FORSKOLIN UP C2.WP GLYCOLYSIS AND GLUCONEOGENESIS C2.WP PENTOSE PHOSPHATE METABOLISM C2.PID LKB1 PATHWAY C2.RAMPON ENRICHED LEARNING ENVIRONMENT LATE UP C2.KEGG MEDICUS REFERENCE REGULATION OF GF RTK RAS ERK SIGNALING RASGAP C2.REACTOME FORMATION OF WDR5 CONTAINING HISTONE MODIFYING COMPLEXES C2.BRUNEAU HEART GREAT VESSELS AND VALVULOGENESIS C2.BRUNEAU HEART GREAT VESSELS AND VALVULOGENESIS C2.BRUNEAU HEART GREAT VESSELS AND VALVULOGENESIS C2.BRAELDE DIABETIC NEPHROPATHY DN				
C2.KYNG NORMAL AGING UP C2.REACTOME APOPTOSIS C2.BARRIER COLON CANCER RECURRENCE DN C2.BALDWIN PRKCI TARGETS UP C2.REACTOME EVASION BY RSV OF HOST INTERFERON RESPONSES C2.REACTOME NUCLEAR ENVELOPE NE REASSEMBLY C2.IBRAHIM NRF2 UP C2.REACTOME TGFBR3 REGULATES TGF BETA SIGNALING C2.GRUETZMANN PANCREATIC CANCER UP C2.REACTOME EVASION BY RSV OF HOST INTERFERON C2.GRUETZMANN PANCREATIC CANCER UP C2.REACTOME FOR DOWNREGULATION C2.REACTOME EGFR DOWNREGULATION C2.REACTOME SIGNALING BY VEGF C2.ABRAHAM ALPC VS MULTIPLE MYELOMA DN C2.CHANDRAN METASTASIS UP C2.WP MFAP5MEDIATED OVARIAN CANCER CELL MOTILITY AND INVASIVENESS C2.REACTOME VEGFR2 MEDIATED VASCULAR PERMEABILITY C2.REACTOME RHOC GTPASE CYCLE C2.TAKAO RESPONSE TO UVB RADIATION DN C2.WEIGEL OXIDATIVE STRESS BY TBH AND H2OZ				
c2.WEIGEL OXIDATIVE STRESS BY TBH AND H2O2 c2.OSMAN BLADDER CANCER UP c2.YANG BREAST CANCER ESR1 LASER DN c2.REACTOME PROTEIN UBIQUITINATION c2.BIOCARTA WNT PATHWAY c2.KAYO AGING MUSCLE DN c2.BRUNEAU SEPTATION VENTRICULAR c2.REACTOME GASTRIN CREB SIGNALLING PATHWAY VIA PKC AND MAPK c2.WP MAPK PATHWAY IN CONGENITAL THYROID CANCER c2.KEGG MEDICUS REFERENCE GLUCONEOGENESIS c2.REACTOME SODIUM COUPLED PHOSPHATE COTRANSPORTERS c2.LEE METASTASIS AND RNA PROCESSING UP c2.REACTOME TIE2 SIGNALING c2.REACTOME SIGNALING BY NOTCH c2.PID AR PATHWAY c2.REACTOME SIGNALING BY HEDGEHOG c2.PHESSE TARGETS OF APC AND MBD2 DN c2.PHESSE TARGETS OF APC AND MBD2 DN c2.PHESSE TARGETS OF APC AND MBD2 DN c2.PIDACATRA RANBP2 PATHWAY				
C2.REACTOME EPH EPHRIN SIGNALING C2.HAHTOLA MYCOSIS FUNGOIDES UP C2.BIOCARTA IL4 PATHWAY C2.GU PDEF TARGETS UP C2.SIG IL4RECEPTOR IN B LYPHOCYTES C2.BIOCARTA CLASSIC PATHWAY C2.WP CALASSIC PATHWAY C2.WP KALLMANN SYNDROME C2.WICK RESPONSE TO PROC TREATMENT DN C2.WP RUBINSTEINTAYBI SYNDROME 1 C2.WP RUBINSTEINTAYBI SYNDROME 1 C2.SPIELMAN LYMPHOBLAST EUROPEAN VS ASIAN DN C2.BERENJENO TRANSFORMED BY RHOA FOREVER UP C2.AIYAR COBRA1 TARGETS DN C2.REACTOME SARS COV 2 HOST INTERACTIONS C2.WP HDAC6 INTERACTIONS IN THE CENTRAL NERVOUS SYSTEM C2.WENG POR TARGETS LIVER UP C2.REACTOME MITOCHONDRIAL FATTY ACID BETA OXIDATION OF UNSATURATED FATTY ACIDS C2.REACTOME DNA REPLICATION PRE INITIATION C2.REACTOME A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS				
C2.LIN APC TARGETS C2.REACTOME ZYGOTIC GENOME ACTIVATION ZGA C2.BAB BRCA1 TARGETS UP C2.WP INVOLVEMENT OF SECRETASE IN NEURODEGENERATIVE DISEASES C2.REACTOME ACTIVATED NTRK2 SIGNALS THROUGH FYN C2.OUYANG PROSTATE CANCER PROGRESSION DN C2.WP WNT SIGNALING WP363 C2.REACTOME TRANSLESION SYNTHESIS BY POLH C2.BIOCARTA NFAT PATHWAY C2.PID RETINOIC ACID PATHWAY C2.PID RETINOIC ACID PATHWAY C2.BIOCARTA AKAP13 PATHWAY C2.TURJANSKI MAPK8 AND MAPK9 TARGETS C2.MORI EMU MYC LYMPHOMA BY ONSET TIME DN C2.BIOCARTA TCR PATHWAY C2.BIOCARTA TCR PATHWAY C2.BIOCARTA TCR PATHWAY C2.BIOCARTA TCR PATHWAY C2.COLOCARTA TOR PATHWAY C2.COLOCARTA TOR PATHWAY C2.COLOCARTA TOR PATHWAY C2.COLOCARTA TOR PATHWAY C3.COLOCARTA TOR PATHWAY C4.COLOCARTA TOR PATHWAY C4.COLOCARTA TOR PATHWAY C5.COLOCARTA TOR PATHWAY C5.COLOC				
c2.REACTOME TICAM1 RIP1 MEDIATED IKK COMPLEX RECRUITMENT c2.REACTOME SARS COV INFECTIONS c2.DACOSTA UV RESPONSE VIA ERCC3 COMMON DN c2.FERRANDO T ALL WITH MLL ENL FUSION DN c2.REACTOME PROTEIN HYDROXYLATION c2.REACTOME MEMBRANE TRAFFICKING c2.PASINI SUZ12 TARGETS DN c2.REACTOME NEF MEDIATED DOWNREGULATION OF MHC CLASS I COMPLEX CELL SURFACE EXPRESSION c2.REACTOME SUMOYLATION OF TRANSCRIPTION COFACTORS c2.WP EGFR TYROSINE KINASE INHIBITOR RESISTANCE c2.REACTOME DEFECTIVE EXT2 CAUSES EXOSTOSES 2 c2.KEGG MEDICUS REFERENCE GLUTATHIONE BIOSYNTHESIS c2.REACTOME ACTIVATED NTRK3 SIGNALS THROUGH PI3K c2.PEACTOME ACTIVATED NTRK3 SIGNALS THROUGH PI3K c2.PEACTOME SEMAND EPITHELIAL TO MESENCHYMAL TRANSITION DN c2.REACTOME SEMAND MEDIATED INHIBITION OF CELL ATTACHMENT AND MIGRATION c2.SCHAEFFER PROSTATE DEVELOPMENT AND CANCER BOX3				
c2.LUI THYROID CANCER PASS PPARG UP c2.BIOCARTA RANMS PATHWAY c2.KEGG DORSO VENTRAL AXIS FORMATION c2.REACTOME NOTCH4 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS c2.STANHILL HRAS TRANSFROMATION UP c2.REACTOME ESR MEDIATED SIGNALING c2.LIM MAMMARY LUMINAL MATURE DN c2.REACTOME CDH11 HOMOTYPIC AND HETEROTYPIC INTERACTIONS c2.WP TGFBETA SIGNALING IN THYROID CELLS FOR EPITHELIALMESENCHYMAL TRANSITION c2.REACTOME ISG15 ANTIVIRAL MECHANISM c2.ACEVEDO NORMAL TISSUE ADJACENT TO LIVER TUMOR UP c2.REACTOME SIGNALING BY FGFR c2.DAZARD RESPONSE TO UV SCC UP c2.REACTOME VESICLE MEDIATED TRANSPORT c2.DAZARD RESPONSE TO UV NHEK UP c2.REACTOME FCERI MEDIATED TRANSPORT c2.DAZARD RESPONSE TO UV NHEK UP c2.REACTOME FCERI MEDIATED MAPK ACTIVATION c2.WP GLIOBLASTOMA SIGNALING c2.FARDIN HYPOXIA 11				
C2.WP METABOLIC REPROGRAMMING IN PANCREATIC CANCER C2.REACTOME SEPARATION OF SISTER CHROMATIOS C2.REACTOME BETA OXIDATION OF DECANOYL COA TOO ACTANOYL COA COA COA C2.REACTOME ALPHA PROTEIN KINASE 1 SIGNALING PATHWAY C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED OPTN TO PINK PARKIN MEDIATED AUTOPHAGOSOME FORMATION C2.MORI PLASMA CELL UP C2.WP PHYSICOCHEMICAL FEATURES AND TOXICITYASSOCIATED PATHWAYS C2.BAE BRCA1 TARGETS DN C2.PUIFFE INVASION INHIBITED BY ASCITES UP C2.REACTOME TRAF6 MEDIATED IRF7 ACTIVATION IN TLR7 8 OR 9 SIGNALING C2.REACTOME SARS COV 2 INFECTION C2.NOSHIDA LIVER CANCER SUBCLASS S1 C2.NABA MATRISOME HIGHLY METASTATIC BREAST CANCER C2.REACTOME MTOR SIGNALLING C2.REACTOME MTOR SIGNALING C2.REACTOME MTOR SIGNALING C2.REACTOME MTOR SIGNALING C2.KEGG MEDICUS VARIANT DUPLICATION OR MUTATION ACTIVATED FLT3 TO RAS PI3K SIGNALING PATHWAY C2.KEGG MEDICUS VARIANT LOSS OF VHL TO HIF 1 SIGNALING PATHWAY C2.KEGG MEDICUS VARIANT LOSS OF VHL TO HIF 1 SIGNALING PATHWAY C2.REACTOME APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS				
c2.REACTOME SIGNALING BY NTRKS c2.REACTOME REGULATION OF INNATE IMMUNE RESPONSES TO CYTOSOLIC DNA c2.JOHNSTONE PARVB TARGET'S 2 UP c2.GRASEMANN RETINOBLASTOMA WITH 6P AMPLIFICATION c2.FALVELLA SMOKERS WITH LUNG CANCER c2.REACTOME PROGRAMMED CELL DEATH c2.REACTOME ABERRANT REGULATION OF MITOTIC EXIT IN CANCER DUE TO RB1 DEFECTS c2.WP TYPE 2 PAPILLARY RENAL CELL CARCINOMA c2.REACTOME TRANSCRIPTIONAL REGULATION BY RUNX1 c2.REACTOME ATIVATION OF BH3 ONLY PROTEINS c2.TARTE PLASMA CELL VS B LYMPHOCYTE UP c2.REACTOME APOPTOTIC EXECUTION PHASE c2.LI CYTIDINE ANALOGS CYCTOTOXICITY c2.RUAN RESPONSE TO TROGLITAZONE UP c2.KEGG UBIQUITIN MEDIATED PROTEOLYSIS c2.ZHENG RESPONSE TO ARSENITE DN c2.PID ALK2 PATHWAY				
c2.REACTOME EXTRA NUCLEAR ESTROGEN SIGNALING c2.WEIGEL OXIDATIVE STRESS RESPONSE c2.LI DCP2 BOUND MRNA c2.REACTOME SIGNALING BY PDGF c2.REACTOME PYRUVATE METABOLISM c2.DER IFN GAMMA RESPONSE DN c2.REACTOME SIGNALING BY ERBB2 c2.WY CYTOSINE METHYLATION c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 23 c2.ZHANG RESPONSE TO CANTHARIDIN DN c2.ZHANG RESPONSE TO CANTHARIDIN DN c2.ZHAN V1 LATE DIFFERENTIATION GENES UP c2.WY LHBX TARGETS 3 DN c2.CREIGHTON AKT1 SIGNALING VIA MTOR UP c2.MURAKAMI UV RESPONSE 1HR UP c2.GOLDRATH HOMEOSTATIC PROLIFERATION c2.LI LUNG CANCER c2.LIEN BREAST CARCINOMA METAPLASTIC c2.REACTOME INTERLEUKIN 1 SIGNALING				patho_cat_name • Nerve sheath tumors • Spindle and epithelioid tumors • Gliomas
c2.GOTZMANN EPITHELIAL TO MESENCHYMAL TRANSITION UP C2.DACOSTA UV RESPONSE VIA ERCC3 DN c2.REACTOME NON INTEGRIN MEMBRANE ECM INTERACTIONS c2.PID NOTCH PATHWAY c2.BIOCARTA NPC PATHWAY c2.BORN INTEGRIN C3.REACTOME NR1H3 NR1H2 REGULATE GENE EXPRESSION LINKED TO CHOLESTEROL TRANSPORT AND EFFLUX c2.KEGG MEDICUS REFERENCE HIF 1 SIGNALING PATHWAY c2.DORN ADENOVIRUS INFECTION 24HR DN c2.WP KETOGENESIS AND KETOLYSIS c2.REACTOME NEGATIVE REGULATION OF FGFR2 SIGNALING c2.HEBERT MATRISOME TNBC BONE METASTASIS c2.KEGG MEDICUS ENV FACTOR NICOTINE NIK TO PI3K SIGNALING PATHWAY c2.GAZDA DIAMOND BLACKFAN ANEMIA PROGENITOR UP c2.REACTOME SIGNALING BY FLT3 ITD AND TKD MUTANTS c2.BONOME OVARIAN CANCER POOR SURVIVAL UP c2.REACTOME SIGNALING BY FLT3 ITD AND TKD MUTANTS c2.BONOME OVARIAN CANCER POOR SURVIVAL UP c2.NGUYEN NOTCH TARGETS UP c2.JIANG MELANOMA TRM5 CD8				 Glioneuronal tumors
C2.REACTOME AMYLOID FIBER FORMATION C2.KEGG MEDICUS REFERENCE IGF IGF1R PI3K SIGNALING PATHWAY C2.WP NETRINUNC5B SIGNALING C2.REACTOME RHOJ GTPASE CYCLE C2.REACTOME INHIBITION OF THE PROTEOLYTIC ACTIVITY OF APC C REQUIRED FOR THE ONSET OF ANAPHASE BY MITOTIC SPINDLE CHECKPOINT COMPONENTS C2.BURTON ADIPOGENESIS 9 C2.KEGG MEDICUS REFERENCE EGF EGFR PLCG CAMK SIGNALING PATHWAY C2.FERRANDO LYL1 NEIGHBORS C2.REACTOME SIGNALING PATHWAY C2.REACTOME SIGNALING PATHWAY C2.REACTOME SIGNALING PATHWAY C2.REACTOME METABOLISM OF RNA C2.WP GLYCOGEN SYNTHESIS AND DEGRADATION C2.LEE CALORIE RESTRICTION MUSCLE UP C2.REACTOME NONCANONICAL ACTIVIATION OF NOTCH3 C2.WP KLEEFSTRA SYNDROME C2.REACTOME RHOH GTPASE CYCLE C2.CAFFAREL RESPONSE TO THC SHR 3 UP C2.BICCARTA AGR PATHWAY				
C2.PID HDAC CLASSI PATHWAY C2.MYLLYKANGAS AMPLIFICATION HOT SPOT 17 C2.BRACHAT RESPONSE TO CAMPTOTHECIN DN C2.KEGG MEDICUS REFERENCE ITGA B TALIN VINCULIN SIGNALING PATHWAY C2.WEIGEL OXIDATIVE STRESS BY HNE AND H202 C2.SASSON RESPONSE TO FORSKOLIN DN C2.WP H19 RBE2F1 AND CDKBETACATENIN IN COLORECTAL CANCER C2.REACTOME MITOCHONDRIAL PROTEIN DEGRADATION C2.REACTOME ESTROGEN DEPENDENT GENE EXPRESSION C2.REACTOME ESTROGEN DEPENDENT GENE EXPRESSION C2.REACTOME SIGNAL STIMULATION UP C2.IKEDA MIR1 TARGETS DN C2.REACTOME ROBO RECEPTORS BIND AKAP5 C2.TOMLINS PROSTATE CANCER DN C2.REACTOME ROBO RECEPTORS BIND AKAP5 C2.TOMLINS PROSTATE CANCER DN C2.REACTOME ALPHA LINOLENIC OMEGAS AND LINOLEIC OMEGAG ACID METABOLISM C2.REACTOME SIGNALING BY FGFR 1 IN DISEASE C2.MURAKAMI UV RESPONSE 6HR UP				
c2.KEGG MEDICUS ENV FACTOR METALS TO NFKB SIGNALING PATHWAY c2.BIOCARTA DICER PATHWAY c2.BIOCARTA DICER PATHWAY c2.WP PATHWAYS AFFECTED IN ADENOID CYSTIC CARCINOMA c2.REACTOME CAMK IV MEDIATED PHOSPHORYLATION OF CREB c2.REACTOME TRAFFICKING OF AMPA RECEPTORS c2.MARCHINI TRABECTEDIN RESISTANCE DN c2.WP BRAINDERIVED NEUROTROPHIC FACTOR BDNF SIGNALING c2.BOYAULT LIVER CANCER SUBCLASS G3 UP c2.DAVIES MULTIPLE MYELOMA VS MGUS DN c2.KEGG MEDICUS VARIANT AMPLIFIED FGFR TO PI3K SIGNALING PATHWAY c2.BYSTRYKH HEMATOPOIESIS STEM CELL AND BRAIN QTL CIS c2.REACTOME INITIATION OF NUCLEAR ENVELOPE NE REFORMATION c2.REACTOME RESPIRATORY ELECTRON TRANSPORT c2.DAZARD UV RESPONSE CLUSTER G2 c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO REST MEDIATED TRANSCRIPTIONAL REPRESSION c2.CHANG POUSF1 TARGETS UP c2.BOGNI TREATMENT RELATED MYELOID LEUKEMIA DN				
c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS TURQUOISE UP c2.REACTOME ASSEMBLY OF THE ORC COMPLEX AT THE ORIGIN OF REPLICATION c2.SA B CELL RECEPTOR COMPLEXES c2.WP PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS FSGS c2.PID MYC REPRESS PATHWAY c2.DER IFN BETA RESPONSE UP c2.KEGG MEDICUS REFERENCE N GLYCAN BIOSYNTHESIS c2.REACTOME RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN BCR SIGNALING c2.FRIDMAN SENESCENCE UP c2.REACTOME ATTACHMENT AND ENTRY c2.SIMBULAN UV RESPONSE NORMAL DN c2.JOHNSTONE PARVB TARGETS 1 DN c2.VIETOR IFRD1 TARGETS c2.WP INSULIN SIGNALING IN ADIPOCYTES DIABETIC CONDITION c2.WP INSULIN SIGNALING IN ADIPOCYTES DIABETIC CONDITION c2.BIOCARTA PS3HYPOXIA PATHWAY c2.KEGG MEDICUS REFERENCE CXCL12 CXCR4 PKC ERK SIGNALING PATHWAY c2.HASINA NOL7 TARGETS UP				
C2.BIOCARTA STATHMIN PATHWAY C2.JIANG MELANOMA TRM7 CD8 C2.REACTOME PLATELET SENSITIZATION BY LDL C2.KEGG MEDICUS REFERENCE ESTABLISHMENT OF COHESION C2.REACTOME NOTCH2 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS C2.BIOCARTA MCALPAIN PATHWAY C2.WP IL3 SIGNALING C2.MAINA VHL TARGETS DN C2.REACTOME TRANSLATION OF REPLICASE AND ASSEMBLY OF THE REPLICATION TRANSCRIPTION COMPLEX C2.WP MODULATION OF PISKAKTMTOR SIGNALING BY BIOACTIVE SPHINGOLIPIDS C2.REACTOME CHROMATIN MODIFYING ENZYMES C2.SCHLOSSER SERUM RESPONSE AUGMENTED BY MYC C2.REACTOME COOPERATION OF PDCL PHLP1 AND TRIC CCT IN G PROTEIN BETA FOLDING C2.BIOCARTA EPHA4 PATHWAY C2.WP REGULATION OF WNT BCATENIN SIGNALING BY SMALL MOLECULE COMPOUNDS C2.ZHU CMV 24 HR UP C2.REACTOME CYPOPROTECTION BY HMOX1 C2.PID REG GR PATHWAY C2.REACTOME CYPOPROTECTION BY HMOX1 C2.PID REG GR PATHWAY				
C2.REACTOME HIV INFECTION C2.REACTOME MITOTIC METAPHASE AND ANAPHASE C2.SWEET KRAS TARGETS UP C2.NABA MATRISOME METASTATIC COLORECTAL LIVER METASTASIS C2.PUJANA BREAST CANCER WITH BRCA1 MUTATED DN C2.KEGG ANTIGEN PROCESSING AND PRESENTATION C2.KEGG ANTIGEN PROCESSING AND PRESENTATION C2.KEGG ANTIGEN PROCESSING BOOK OF CYCLIN B CDK1 COMPLEX C2.REACTOME CHK1 CHK2 CDS1 MEDIATED INACTIVATION OF CYCLIN B CDK1 COMPLEX C2.REACTOME EPIGENETIC REGULATION OF GENE EXPRESSION C2.PID LIA PATHWAY C2.MOOTHA PGC C2.SASSON RESPONSE TO GONADOTROPHINS DN C2.KEGG MEDICUS REFERENCE PDGF PDGFR PI3K SIGNALING PATHWAY C2.REACTOME NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION C2.HU GENOTOXIN ACTION DIRECT VS INDIRECT 24HR C2.WE VALPROIC ACID PATHWAY				
C2.HIRSCH CELLULAR TRANSFORMATION SIGNATURE DN C2.REACTOME RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF MYELIOID CELLS C2.GENTILE UV RESPONSE CLUSTER D5 C2.OSMAN BLADDER CANCER DN C2.REACTOME MYOCLONIC EPILLEPSY OF LAFORA C2.PID ERA GENOMIC PATHWAY C2.REACTOME REGULATION OF GENE EXPRESSION IN LATE STAGE BRANCHING MORPHOGENESIS PANCREATIC BUD PRECURSOR CELLS C2.IVANOVA HEMATOPOIESIS STEM CELL SHORT TERM C2.KYNG ENVIRONMENTAL STRESS RESPONSE NOT BY UV IN OLD C2.REACTOME CREB1 PHOSPHORYLATION THROUGH THE ACTIVATION OF CAMKII CAMKK CAMKIV CASCASDE C2.REACTOME CARGO RECOGNITION FOR CLATHRIN MEDIATED ENDOCYTOSIS C2.BIOCARTA BAD PATHWAY C2.DI MARTINO MATRISOME HIGHLY PROLIFERATIVE HNSCC C2.TURASHVILI BREAST LOBULAR CARCINOMA VS DUCTAL NORMAL UP C2.REACTOME DISEASES OF SIGNAL TRANSDUCTION BY GROWTH FACTOR RECEPTORS AND SECOND MESSENGERS				
c2.PID ILG 7 PATHWAY c2.BIOCARTA PS1 PATHWAY c2.WP KIT RECEPTOR SIGNALING c2.RAMASWAMY METASTASIS UP c2.PID ARF6 TRAFFICKING PATHWAY c2.KEGG MEDICUS PATHOGEN HCV CORE TO RXRA LXRA MEDIATED TRANSCRIPTION c2.WP SEROTONIN RECEPTOR 2 AND ELKSRFGATA4 SIGNALING c2.REACTOME RK MAPK TARGETS c2.MANN RESPONSE TO AMIFORSTINE UP c2.WP MACROPHAGESTIMULATING PROTEIN MSP SIGNALING c2.WP BDNFTRKS SIGNALING c2.WP SEROTONIN HTR1 GROUP AND FOS PATHWAY c2.MARSON FOXP3 TARGETS UP c2.KIM WT1 TARGETS 8HR UP c2.REACTOME PROCESSING OF CAPPED INTRONLESS PRE MRNA				
C2. STONER ESOPHAGEAL CARCINOGENESIS UP C2. IWANAGA E2F1 TARGETS NOT INDUCED BY SERUM C2. STARK PREFRONTAL CORTEX 22Q11 DELETION DN C2. KEGG MEDICUS REFERENCE EGF EGFR RAS PI3K SIGNALING PATHWAY C2. BIOCARTA PDZS PATHWAY C2. FIDMAN IMMORTALIZATION DN C2. GALLUZZI PREVENT MITOCHONDIAL PERMEABILIZATION C2. FILOMORY C2. GALLUZZI PREVENT MITOCHONDIAL PERMEABILIZATION C2. FILOMORY C3. GALLUZZI PREVENT MITOCHONDIAL PERMEABILIZATION C4. FILOMORY C5. GALLUZZI PREVENT MITOCHONDIAL PERMEABILIZATION C5. GALLUZZI PERMEABIL				
C2.KEGG MEDICUS VARIANT ERBB2 OVEREXPRESSION TO EGF JAK STAT SIGNALING PATHWAY C2.REACTOME EPHRIN SIGNALING C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED ATP1A1 TO ANGIOTENSIN ALDOSTERONE SIGNALING PATHWAY C2.REACTOME POTENTIAL THERAPEUTICS FOR SARS C2.LU A GING BRAIN UP C2.MALTA CURATED STEMNESS MARKERS C2.FOURNIER ACINAR DEVELOPMENT EARLY DN C2.WP MIRNA BIOGENESIS C2.KASLER HDAC7 TARGETS 1 DN C2.GENTILE UV RESPONSE CLUSTER D9 C2.PURBEY TARGETS OF CTBP1 AND SATB1 UP C2.WP PHOTODYNAMIC THERAPYINDUCED HIP1 SURVIVAL SIGNALING C2.WP MITOCHONDRIAL COMPLEX II ASSEMBLY C2.KEGG MEDICUS PATHOGEN KSHV VFLIP TO NFKB SIGNALING PATHWAY C2.WEIGEL OXIDATIVE STRESS BY HNE AND TBH C2.BULD CTNNB1 ONCOGENIC SIGNATURE C2.XU HGF TARGETS REPRESSED BY AKT1 UP C2.SWEET LUNG CANCER KRAS UP C2.MARTINEZ RESPONSE TO TRABECTEDIN DN				
c2.MARTINEZ RESPONSE TO TRABECTEDIN DN c2.GAZDA DIAMOND BLACKFAN ANEMIA MYELOID DN c2.GAZDA DIAMOND BLACKFAN ANEMIA MYELOID DN c2.GERING BLOOD HDL CHOLESTEROL QTL CIS c2.REACTOME SIGNALING BY TGFB FAMILY MEMBERS c2.REACTOME SIGNALING c2.CALGO HEX TARGETS UP c2.CALGO HEX TARGETS UP c2.CALGO HEX TARGET SIGNALING c2.CALGO HEX TARGET SIGN				
c2.WP 8Q1123 RB1CC1 COPY NUMBER VARIATION c2.GABRIELY MIR21 TARGETS c2.REACTOME CELLULAR SENESCENCE c2.REACTOME REGULATION OF IFNG SIGNALING c2.GALUZZI PERMEABILIZE MITOCHONDRIA c2.WEST ADRENOCORTICAL CARCINOMA VS ADENOMA DN c2.KEGG MEDICUS REFERENCE ISOLEUCINE DEGRADATION c2.WP AIRWAY SMOOTH MUSCLE CELL CONTRACTION c2.WP AIRWAY SMOOTH MUSCLE CELL CONTRACTION c2.WP COHESIN COMPLEX CORNELIA DE LANGE SYNDROME c2.PARK APL PATHOGENESIS UP c2.PARK APL PATHOGENESIS UP c2.REACTOME LATE ENDOSOMAL MICROAUTOPHAGY c2.REACTOME CYCLIN D ASSOCIATED EVENTS IN G1 c2.WP TCA CYCLE IN SENESCENCE c2.SASAKI TARGETS OF TP73 AND TP63 c2.TURASHVILI BREAST NORMAL DUCTAL VS LOBULAR DN c2.KEGG MEDICUS ENV FACTOR NNK NNN TO P13K SIGNALING PATHWAY NO1350 c2.PID HDAC CLASSIII PATHWAY c2.WP INTERFERON TYPE I SIGNALING c2.REACTOME NFE2L2 REGULATING INTERFERON TYPE I SIGNALING c2.REACTOME NFE2L2 REGULATING INTERFERON TYPE I SIGNALING				
c2.REACTOME NFE2L2 REGULATING INFLAMMATION ASSOCIATED GENES c2.WP MECP2 AND ASSOCIATED RETT SYNDROME c2.REACTOME SIGNALING BY TGFBR3 c2.REACTOME ASPARAGINE N LINKED GLYCOSYLATION c2.KEGG FC GAMMA R MEDIATED PHAGOCYTOSIS c2.REACTOME DEUBIQUITINATION c2.KEGG FC GAMMA R MEDIATED PHAGOCYTOSIS c2.REACTOME DEUBIQUITINATION c2.WP AUTOPHAGY IN PANCREATIC DUCTAL ADENOCARCINOMA c2.MATTIOLI MGUS VS PCL c2.SPIELMAN LYMPHOBLAST EUROPEAN VS ASIAN UP c2.REACTOME RHO GTPASE EFFECTORS c2.REACTOME RHO GTPASE EFFECTORS c2.SAGIV CD24 TARGETS UP c2.REACTOME DNA DAMAGE RECOGNITION IN GG NER c2.WANG TARGETS OF MLL CBP FUSION DN c2.WP MRNA PROTEIN AND METABOLITE INDUCATION PATHWAY BY CYCLOSPORIN A c2.REACTOME ROLE OF ABL IN ROBO SLIT SIGNALING c2.DING LUNG CANCER EXPRESSION BY COPY NUMBER c2.WP ERBB SIGNALING c2.RIZKI TUMOR INVASIVENESS 2D DN c2.ABRAHAM ALPC VS MULTIPLE MYELOMA UP				
C2.ABRAHAM ALPC VS MULTIPLE MYELOMA UP C2.REACTOME (CONVERSION FROM APC C CDC20 TO APC C CDTA) IN LATE ANAPHASE C2.REACTOME P130CAS LINKAGE TO MAPK SIGNALING FOR INTEGRINS C2.REACTOME P130CAS LINKAGE TO MAPK SIGNALING FOR INTEGRINS C2.REACTOME MATURATION OF SARS COV 2 NUCLEOPROTEIN C2.KEGG MEDICUS REFERENCE DRD1 GNAS AC PKA SIGNALING PATHWAY C2.ZHAN V2 LATE DIFFERENTIATION GENES C2.FLECHNER PBL KIDNEY TRANSPLANT REJECTED VS OK DN C2.REACTOME TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM C2.LEI MYB TARGETS C2.BIOCARTA RHO PATHWAY C2.REACTOME PTK6 REGULATES CELL CYCLE C2.KYNG DNA DAMAGE DN C2.REACTOME PTK6 REGULATES CELL CYCLE C2.KYNG DNA DAMAGE DN C2.REACTOME CIRCADIAN CLOCK C2.REACTOME CIRCADIAN CLOCK C2.REACTOME GPERT SIGNALING C2.WP NAD METABOLISM IN ONCOGENEINDUCED SENESCENCE AND MITOCHONDRIAL DYSFUNCTIONASSOCIATED SENESCENCE				
c2.WP NAD METABOLISM IN ONCOGENEINDUCED SENESCENCE AND MITOCHONDRIAL DYSFUNCTIONASSOCIATED SENESCENCE c2.REACTOME RNA POLYMERASE I TRANSCRIPTION c2.KEGG MEDICUS REFERENCE NOTCH PROTEOLYTIC ACTIVATION c2.FAELT B CLL WITH VH3 21 UP c2.REACTOME PRC2 METHYLATES HISTONES AND DNA c2.LUI SOX4 TARGETS DN c2.WP APOPTOSISRELATED NETWORK DUE TO ALTERED NOTCH3 IN OVARIAN CANCER c2.PID HIF1 TFPATHWAY c2.LUI THYROID CANCER CLUSTER 1 c2.SCHAEFFER PROSTATE DEVELOPMENT AND CANCER CLUSTER 1 c2.KEGG MEDICUS REFERENCE ACTIVATION OF PRC2.2 BY UBIQUITINATION OF H2AK119 c2.REACTOME SIGNALING BY WNT IN CANCER c2.REACTOME SIGNALING BY WNT IN CANCER c2.REACTOME HATS ACETYLATE HISTONES c2.REACTOME HATS ACETYLATE HISTONES c2.REACTOME AND KS IGNALING FOR INTEGRINS c2.BOYAULT LIVER CANCER SUBCLASS G123 UP c2.NADERI BREAST CANCER PROGNOSIS DN c2.WP COPPER HOMEOSTASIS c2.PID AJDISS ZPATHWAY c2.ONKEN UVFAL MELANOMA UP				
c2.ONKEN UVEAL MELANOMA UP c2.WP ENDOMETRIAL CANCER c2.BENPORATH MYC TARGETS WITH EBOX c2.BENPORATH MYC TARGETS WITH EBOX c2.BIOCARTA PGC1A PGT1A PGT1				
c2.REACTOME TGFBR3 EXPRESSION c2.WP STEROL REGULATORY ELEMENTBINDING PROTEINS SREBP SIGNALING c2.REACTOME MATURATION OF SPIKE PROTEIN c2.ZHAN MULTIPLE MYELOMA UP c2.KOINUMA COLON CANCER MSI UP c2.ZHAN LATE DIFFERENTIATION GENES UP c2.WP IL1 SIGNALING c2.BLUM RESPONSE TO SALIRASIB UP c2.KEGG MEDICUS REFERENCE MYOSTATIN SIGNALING PATHWAY c2.REACTOME REGULATION OF NFE2L2 GENE EXPRESSION c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED ATP2B3 TO ANGIOTENSIN ALDOSTERONE SIGNALING PATHWAY c2.SIG PIP3 SIGNALING IN CARDIAL MYOCTES c2.SCHLOSSER MYC TARGETS AND SERUM RESPONSE DN c2.WP CLEAR CELL RENAL CELL CARCINOMA PATHWAYS c2.REACTOME REGULATION OF TBK1 IKK MEDIATED ACTIVATION OF IRF3 IRF7 UPON TLR3 LIGATION c2.REACTOME TCF DEPENDENT SIGNALING IN RESPONSE TO WNT c2.KEGG MEDICUS REFERENCE CREATINE PATHWAY c2.REACTOME TCF DEPENDENT SIGNALING IN RESPONSE TO WNT c2.KEGG MEDICUS REFERENCE CREATINE PATHWAY c2.REACTOME TCF DEPENDENT SIGNALING IN RESPONSE TO WNT c2.KEGG MEDICUS REFERENCE CREATINE PATHWAY c2.REACTOME TCF DEPENDENT SIGNALING IN RESPONSE TO WNT c2.KEGG MEDICUS REFERENCE CREATINE PATHWAY				
c2.PID BETA CATENIN NUC PATHWAY c2.THEILGAARD NEUTROPHIL AT SKIN WOUND DN c2.TOMIDA METASTASIS UP c2.VERRECCHIA DELAYED RESPONSE TO TGFB1 c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 16 c2.KEGG MEDICUS VARIANT SCRAPIE CONFORMATION PRPSC TO MGLUR5 CA2 APOPTOTIC PATHWAY c2.REACTOME NEGATIVE REGULATION OF FLT3 c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED PRKN TO MGLUR1 SIGNALING BY WNT c2.REACTOME SIGNALING BY WNT c2.WP TRANSCRIPTION COFACTORS SKI AND SKIL PROTEIN PARTNERS c2.GERHOLD RESPONSE TO TZD DN c2.ENK UV RESPONSE TO TZD DN c2.ENK UV RESPONSE TO TZD c2.KYNG WERNER SYNDROM UP c2.KIYNG WERNER SYNDROM UP c2.KIYNG WERNER SYNDROM AND NORMAL AGING DN c2.REACTOME SIGNALING BY NOTCH1 PEST DOMAIN MUTANTS IN CANCER c2.CYNKEN UV FLATE DN c2.REACTOME SIGNALING BY NOTCH1 PEST DOMAIN MUTANTS IN CANCER c2.CYNKEN UV FLATE DN c2.CYNKEN UV FLATE DN c2.REACTOME SIGNALING BY NOTCH1 PEST DOMAIN MUTANTS IN CANCER				
C2.ONKEN UVEAL MELANOMA DN C2.WANG ESOPHAGUS CANCER VS NORMAL DN C2.REACTOME FORMATION OF TC NER PRE INCISION COMPLEX C2.WP ESTRADIOL REGULATION IN PORTOSINUSOIDAL VASCULAR DISEASE C2.RHEIN ALL GLUCCORTICOID THERAPY DN C2.KEGG MEDICUS REFERENCE BLOCKING UBIQUITINATION OF H2AK119 BY CK2 C2.REACTOME MITOTIC G2 C2 M PHASES C2.KEGG FOCAL ADHESION C2.REACTOME INTERLEUKIN 17 SIGNALING C2.PID RHOA PATHWAY C2.HU ANGIOGENESIS UP C2.DAIRKEE CANCER PRONE RESPONSE BPA E2 C2.BIOCARTA LDL PATHWAY C2.WP FOCAL ADHESION C2.REACTOME G BETA GAMMA SIGNALLING THROUGH CDC42 C2.WP BLADDER CANCER C2.WP EPO RECEPTOR SIGNALING C2.REACTOME MISCHILLING THROUGH CDC42 C2.WP EPO RECEPTOR SIGNALING C2.REACTOME DNA METHYLATION				
c2.REACTOME DNA METHYLATION c2.MAYBURD RESPONSE TO L663536 DN c2.DESERT STEM CELL HEPATOCELLULAR CARCINOMA SUBCLASS UP c2.REACTOME CELLULAR RESPONSE TO HEAT STRESS c2.BARRIER CANCER RELAPSE NORMAL SAMPLE DN c2.WP DEGRADATION PATHWAY OF SPHINGOLIPIDS INCLUDING DISEASES c2.KAYO CALORIE RESTRICTION MUSCLE UP c2.ID EPO PATHWAY c2.REACTOME TRANSPORT OF FATTY ACIDS c2.WP ANDROGEN RECEPTOR NETWORK IN PROSTATE CANCER c2.FLECHNER BIOPSY KIDNEY TRANSPLANT REJECTED VS OK DN c2.AMIT SERVIN RESPONSE 20 HELA c2.GENTILE UV RESPONSE CLUSTER D6 c2.WONG MITOCHONDRIA GENE MODULE c2.REACTOME SARS COV 2 TARGETS PDZ PROTEINS IN CELL CELL JUNCTION c2.REACTOME SARS COV 2 TARGETS PDZ PROTEINS IN CELL CELL JUNCTION c2.REACTOME RUNX2 REGULATES GENES INVOLVED IN CELL MIGRATION				
c2.REACTOME RUNX2 REGULATES GENES INVOLVED IN CELL MIGRATION c2.MOHANKUMAR HOXA1 TARGETS UP c2.BERNARD PPAPDC1B TARGETS UP c2.BERNARD PPAPDC1B TARGETS UP c2.BERNARD PPAPDC1B TARGETS UP c2.BIOCARTA RAC1 PATHWAY c2.WP HEMATOPOIETIC STEM CELL GENE REGULATION BY GABP ALPHABETA COMPLEX c2.REACTOME INACTIVATION OF CDC42 AND RAC1 c2.KEGG MEDICUS PATHOGEN HBV HBX TO CREB MEDIATED TRANSCRIPTION c2.REACTOME SIGNALING BY INSULIN RECEPTOR c2.KEGG MEDICUS ENV FACTOR PARAQUAT TO FAS JNK SIGNALING PATHWAY c2.MONTERO THYROID CANCER POOR SURVIVAL DN c2.KABA FAILED HEART VENTRICLE DN c2.CMAB FAILED HEART VENTRICLE DN c2.CMP TUMOR SUPPRESSOR ACTIVITY OF SMARCB1 c2.CLASPER LYMPHATIC VESSELS DURING METASTASIS DN c2.PRAMOONJAGO SOX4 TARGETS DN c2.REACTOME ROLE OF LAT2 NTAL LAB ON CALCIUM MOBILIZATION c2.WP RAC1PAK1P38MMP2 PATHWAY c2.KEGG MEDICUS REFERENCE TGFA EGFR PIJK SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE TGFA EGFR PIJK SIGNALING PATHWAY c2.REACTOME COMPLEX III ASSEMBLY				
c2.REACTOME COMPLEX III ASSEMBLY c2.PID HIF2PATHWAY c2.PID HIF2PATHWAY c2.MALONEY RESPONSE TO 17AAG UP c2.WALONEY RESPONSE TO 17AAG UP c2.BURTON ADIPOGENESIS 4 c2.TARTE PLASMA CELL VS PLASMABLAST DN c2.ZHAN EARLY DIFFERENTIATION GENES UP c2.WP HEPATITIS C AND HEPATOCELLULAR CARCINOMA c2.KEGG MEDICUS PATHOGEN HIV GP120 TO CXCR4 GNAI PI3K BAD SIGNALING PATHWAY c2.SHAFFER IRF4 TARGETS IN MYELOMA VS MATURE B LYMPHOCYTE c2.ULE SPLICING VIA NOVA2 c2.BARRIER COLON CANCER RECURRENCE UP c2.LEIN NEURON MARKERS c2.REACTOME ACTIVATED NOTCH1 TRANSMITS SIGNAL TO THE NUCLEUS c2.SESTO RESPONSE TO UV C4 c2.RUIZ TIC TARGETS UP c2.WANG RESPONSE TO FORSKOLIN UP c2.BIOCARTA P53 PATHWAY c2.ZHAN MULTIPLE MYELOMA SUBGROUPS				
C2.ZHAN MULTIPLE MYELOMA SUBGROUPS C2.KAMIKUBO MYELOID MN1 NETWORK C2.LOPEZ MBD TARGETS C2.PID MYC ACTIV PATHWAY C2.LINDGREN BLADDER CANCER CLUSTER 2A DN C2.HELLEBREKERS SILENCED DURING TUMOR ANGIOGENESIS C2.PETRETTO HEART MASS QTL CIS UP C2.KEGG LYSOSOME C2.REACTOME RHOG GTPASE CYCLE C2.WP ALZHEIMERS DISEASE C2.BASSO HAIRY CELL LEUKEMIA UP C2.YAMASHITA SILENCED BY METHYLATION C2.WOOD EBV EBNA1 TARGETS DN C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED PRKAR1A TO ACTH CORTISOL SIGNALING PATHWAY C2.WP SEBALEIC ACID FORMATION AND METABOLISM C2.BIOCARTA ION PATHWAY C2.WP FBXL10 ENHANCEMENT OF MAPERK SIGNALING IN DIFFUSE LARGE BCLL LYMPHOMA C2.PID FCRER1 PATHWAY				
c2.REACTOME RHO GTPASES ACTIVATE RHOTEKIN AND RHOPHILINS c2.REACTOME MET ACTIVATES PISK AKT SIGNALING c2.DEMAGALHAES AGING DN c2.WP ENVELOPE PROTEINS AND THEIR POTENTIAL ROLES IN EDMD PHYSIOPATHOLOGY c2.KUROKAWA LIVER CANCER EARLY RECURRENCE UP c2.WP LEPTIN AND ADIPONECTIN c2.JOHNSTONE PARVB TARGETS 3 UP c2.REACTOME PP2A MEDIATED DEPHOSPHORYLATION OF KEY METABOLIC FACTORS c2.PID IL8 CXCR2 PATHWAY c2.BIOCARTA CPSF PATHWAY c2.BIOCARTA CPSF PATHWAY c2.CHOMACTED GENES KLK2 AND KLK3 c2.THEILGAARD NEUTROPHIL AT SKIN WOUND UP c2.LAMB CCND1 TARGETS c2.VANHARANTA UTERINE FIBROID WITH 7Q DELETION DN c2.KEGG ERBB SIGNALING PATHWAY c2.HUMME BURKITTS LYMPHOMA DN				
C2. HUMMEL BURRITTS LYMPHOMA DN C2. REACTOME RHOD GTPASE CYCLE C2. WCCLUNG COCAINE REWARD 5D C2. REACTOME PHOSPHORYLATION OF THE APC C C2. WP INTEGRINMEDIATED CELL ADHESION C2. REACTOME E3 UBIQUITIN LIGASES UBIQUITINATE TARGET PROTEINS C2. PID LL2 THATHWAY C2. WP CORTICOTROPINRELEASING HORMONE SIGNALING C2. PID CXCR4 PATHWAY C2. WP PANCREATIC ADENOCARCINOMA PATHWAY C2. REACTOME LEISHMANIAI INFECTION C2. WP AGERAGE PATHWAY C2. LEIN LOCALIZED TO PROXIMAL DENDRITES C2. WP NOTCH SIGNALING WP61 C2. STONER ESOPHAGEAL CARCINOGENESIS DN C2. REACTOME FORMATION OF SENESCENCE ASSOCIATED HETEROCHROMATIC SAHF C2. XU RESPONSE TO TRETINOIN AND NSC682994 UP C2. WYLLYKANGAS AMPLIFICATION HOT SPOT 24 C2. REACTOME INTRACELLULAR SIGNALING BY SECOND MESSENGERS				
c2.REACTOME INTRACELLULAR SIGNALING BY SECOND MESSENGERS c2.WP FLUOROACETIC ACID TOXICITY c2.OUELLET CULTURED OVARIAN CANCER INVASIVE VS LMP UP c2.BIOCARTA CELL2CELL PATHWAY c2.TIEN INTESTINE PROBIOTICS 24HR UP c2.GROSS HYPOXIA VIA ELK3 UP c2.GROSS HYPOXIA VIA ELK3 UP c2.CALER MYC TARGETS UP c2.COLLER MYC TARGETS UP c2.COLLER MYC TARGETS UP c2.PICCALUGA ANGIOIMMUNOBLASTIC LYMPHOMA DN c2.REACTOME SIGNALING BY NUCLEAR RECEPTORS c2.KEGG MEDICUS REFERENCE ADRB3 UCP1 SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE IGF IGFR PI3K NFKB SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE IGF IGFR PI3K NFKB SIGNALING PATHWAY c2.WP SYNAPTIC VESICLE PATHWAY c2.WP SYNAPTIC VESICLE PATHWAY c2.WELCSH BRCA1 TARGETS DN c2.WP MICRORNA FOR TARGETING CANCER GROWTH AND VASCULARIZATION IN GLIOBLASTOMA c2.REACTOME SIGNALING BY ERBB4				
C2.REACTOME SIGNALING BY ERB84 C2.WP 16P112 PROXIMAL DELETION SYNDROME C2.KEGG MTOR SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE CONDENSIN LOADING C2.WEINMANN ADAPTATION TO HYPOXIA UP C2.BIOCARTA CARM ER PATHWAY C2.BRACHAT RESPONSE TO CISPLATIN C2.KEGG GAP JUNCTION C2.MULLIGAN NTF3 SIGNALING VIA INSR AND IGF1R UP C2.REACTOME RAF INDEPENDENT MAPK1 3 ACTIVATION C2.KEGG MEDICUS REFERENCE RELN VLDLR PI3K SIGNALING PATHWAY C2.REACTOME RESPIRATORY SYNCYTIAL VIRUS INFECTION PATHWAY C2.REACTOME RESPIRATORY SYNCYTIAL VIRUS INFECTION PATHWAY C2.REACTOME RESPIRATORY SYNCYTIAL VIRUS INFECTION PATHWAY C3.WP NRF2ARE REGULATION -0.25 0.00 0.25 0.50.		50.25 0.00 0.25 0.5core	0.25 0.00 0.25 0.50	